Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae

Richard R Watkins^{1

2}, Stan Deresinski³

Affiliations

¹ a Department of Internal Medicine , Northeast Ohio Medical University , Rootstown , OH , USA.
² b Division of Infectious Diseases , Cleveland Clinic Akron General , Akron , OH , USA.
³ c Department of Medicine, Division of Infectious Diseases and Geographic Medicine , Stanford University , Stanford , CA , USA.

Editorial

Richard R Watkins et al. Expert Rev Anti Infect Ther. 2017 Oct.

. 2017 Oct;15(10):893-895.

doi: 10.1080/14787210.2017.1380519. Epub 2017 Sep 21.

Richard R Watkins^{1

2}, Stan Deresinski³

¹ a Department of Internal Medicine , Northeast Ohio Medical University , Rootstown , OH , USA.
² b Division of Infectious Diseases , Cleveland Clinic Akron General , Akron , OH , USA.
³ c Department of Medicine, Division of Infectious Diseases and Geographic Medicine , Stanford University , Stanford , CA , USA.

No abstract available

Keywords: Antimicrobial resistance; CRE; ESBL; beta-lactam/beta-lactamase inhibitors; blood stream infections.

Cited by

β-lactam/β-lactamase inhibitor combinations: an update.
Tehrani KHME, Martin NI. Tehrani KHME, et al. Medchemcomm. 2018 Aug 17;9(9):1439-1456. doi: 10.1039/c8md00342d. eCollection 2018 Sep 1. Medchemcomm. 2018. PMID: 30288219 Free PMC article. Review.